BioCentury | Apr 15, 2013
Company News

Recombinant Biocatalysis supply/service, drug discovery news

...The company changed its name to Diversa Corp. Diversa discovers and manufactures enzymes for use in industrial...
...Diversa discovers and manufactures enzymes for use in industrial and chemical processes and drug discovery. Recombinant Biocatalysis...
BioCentury | Apr 15, 2013
Company News

Recombinant BioCatalysis management update

Recombinant BioCatalysis , Sharon Hill, Penn. Business: Supply/Service Hired: Kathleen VanSleen, as VP of finance and administration; formerly CFO, treasurer and assistant secretary of Regent Lighting Corp. WIR Staff...
BioCentury | Nov 17, 2008
Company News

Favrille, MyMedicalRecords.com Inc. deal

...remaining asset is a preclinical panel of anti-CD20 mAbs, which it acquired in 2007 from Diversa Corp....
BioCentury | Dec 3, 2007
Company News

Optimer board of directors update

...Business: Infectious, Gastrointestinal, Cancer Appointed: Anthony Altig, formerly SVP of finance, CFO and secretary of Diversa Corp....
BioCentury | Jun 25, 2007
Company News

Diversa, Celunol Corp. deal

...shareholders will own 24% of the newco, and DVSA shareholders will own the remaining 76%. Diversa Corp....
BioCentury | Jun 18, 2007
Company News

Diversa, Favrille deal

...said it will develop next-generation treatments for non-Hodgkin's lymphoma (NHL). Financial terms were not disclosed. Diversa Corp....
BioCentury | Mar 24, 2007
Financial News

Diversa raises $100M in note deal

DVSA raised $100 million in a bumped-up private placement of convertible senior notes due 2027. The notes bear 5.5% interest and convert into stock at $8.16, which is a 23% premium to the company's close...
BioCentury | Mar 21, 2007
Financial News

Diversa proposes note deal

DVSA proposed to raise $75 million in a private placement of convertible senior notes due 2027. DVSA customizes enzymes for manufacturers in the biofuels, industrial and health and nutrition markets. DVSA, which made the announcement...
BioCentury | Mar 5, 2007
Company News

Diversa, Cargill Inc. deal

...now develop additional enzymes to facilitate further steps in production. Financial terms were not disclosed. Diversa Corp....
BioCentury | Jan 1, 2007
Company News

Diversa, Genomatica Inc. deal

...the multi-year project and is eligible for milestones and royalties. Further terms were not disclosed. Diversa Corp....
Items per page:
1 - 10 of 218
BioCentury | Apr 15, 2013
Company News

Recombinant Biocatalysis supply/service, drug discovery news

...The company changed its name to Diversa Corp. Diversa discovers and manufactures enzymes for use in industrial...
...Diversa discovers and manufactures enzymes for use in industrial and chemical processes and drug discovery. Recombinant Biocatalysis...
BioCentury | Apr 15, 2013
Company News

Recombinant BioCatalysis management update

Recombinant BioCatalysis , Sharon Hill, Penn. Business: Supply/Service Hired: Kathleen VanSleen, as VP of finance and administration; formerly CFO, treasurer and assistant secretary of Regent Lighting Corp. WIR Staff...
BioCentury | Nov 17, 2008
Company News

Favrille, MyMedicalRecords.com Inc. deal

...remaining asset is a preclinical panel of anti-CD20 mAbs, which it acquired in 2007 from Diversa Corp....
BioCentury | Dec 3, 2007
Company News

Optimer board of directors update

...Business: Infectious, Gastrointestinal, Cancer Appointed: Anthony Altig, formerly SVP of finance, CFO and secretary of Diversa Corp....
BioCentury | Jun 25, 2007
Company News

Diversa, Celunol Corp. deal

...shareholders will own 24% of the newco, and DVSA shareholders will own the remaining 76%. Diversa Corp....
BioCentury | Jun 18, 2007
Company News

Diversa, Favrille deal

...said it will develop next-generation treatments for non-Hodgkin's lymphoma (NHL). Financial terms were not disclosed. Diversa Corp....
BioCentury | Mar 24, 2007
Financial News

Diversa raises $100M in note deal

DVSA raised $100 million in a bumped-up private placement of convertible senior notes due 2027. The notes bear 5.5% interest and convert into stock at $8.16, which is a 23% premium to the company's close...
BioCentury | Mar 21, 2007
Financial News

Diversa proposes note deal

DVSA proposed to raise $75 million in a private placement of convertible senior notes due 2027. DVSA customizes enzymes for manufacturers in the biofuels, industrial and health and nutrition markets. DVSA, which made the announcement...
BioCentury | Mar 5, 2007
Company News

Diversa, Cargill Inc. deal

...now develop additional enzymes to facilitate further steps in production. Financial terms were not disclosed. Diversa Corp....
BioCentury | Jan 1, 2007
Company News

Diversa, Genomatica Inc. deal

...the multi-year project and is eligible for milestones and royalties. Further terms were not disclosed. Diversa Corp....
Items per page:
1 - 10 of 218